Experimental cell therapy aims to reset immune system in autoimmune diseases
NCT ID NCT07152223
Summary
This study is testing whether a new type of cell therapy called CD19-BCMA CAR-T is safe and effective for treating several autoimmune connective tissue diseases, including lupus, rheumatoid arthritis, and scleroderma. Researchers will enroll 20 participants at a single center to see if this therapy can reduce disease activity. The treatment involves modifying a patient's own immune cells to potentially target and reset the malfunctioning immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan Taixin Hospital
RECRUITINGDongguan, Guangdong, 523125, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.